This site is intended for health professionals only

At the heart of general practice since 1960

A1B use raises risk of vascular event

The risk of vascular events is increased with many alpha1-adrenergic receptor blockers used for the treatment of benign prostatic hyperplasia, a large meta-analysis shows.

Canadian researchers found A1B use was associated with an overall significant 2.5-fold increase in the risk of developing a vascular event.

But the odds differed depending on the agent used – with alfuzosin increasing risk 1.66-fold, terazosin by 3.7-fold, doxazosin by 3.3-fold and tamsulosin a non-significant 1.4-fold, compared with placebo.

However, all the drugs significantly improved urinary flow rate and symptom signs compared with placebo.

Int J Clin Pract 2008;62:1547-59

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say